A phase I/II study of AIM ACT for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant (HSCT).
Phase of Trial: Phase I/II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs AIM ACT (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 02 Jan 2018 According to a NexImmune media release, the company is planning to initiate the trial in 2018.
- 20 Oct 2017 New trial record
- 17 Oct 2017 According to a NexImmune media release, the Company has completed Pre-IND discussions with the FDA, and expects to submit an IND in 1HQ2018.